CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....